Last reviewed · How we verify
Placebo (human albumin 1%)
Placebo (human albumin 1%) is a Plasma volume expander / Colloid Small molecule drug developed by Biotest. It is currently in Phase 3 development for Placebo control in Phase 3 clinical trial (specific indication unknown).
Human albumin 1% serves as a volume expander and oncotic agent to maintain intravascular fluid balance and plasma colloid osmotic pressure.
Human albumin 1% serves as a volume expander and oncotic agent to maintain intravascular fluid balance and plasma colloid osmotic pressure. Used for Placebo control in Phase 3 clinical trial (specific indication unknown).
At a glance
| Generic name | Placebo (human albumin 1%) |
|---|---|
| Sponsor | Biotest |
| Drug class | Plasma volume expander / Colloid |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Hematology |
| Phase | Phase 3 |
Mechanism of action
Albumin is a naturally occurring plasma protein that increases and maintains oncotic pressure within blood vessels, helping to retain fluid in the intravascular space and prevent fluid shifts into tissues. In clinical use, it is administered intravenously to restore or maintain circulating blood volume in patients with significant fluid loss or hypoproteinemia. As a placebo control in this Phase 3 trial, it provides a physiologically active comparator rather than an inert control.
Approved indications
- Placebo control in Phase 3 clinical trial (specific indication unknown)
Common side effects
- Hypervolemia
- Pulmonary edema
- Allergic reaction
- Fever
Key clinical trials
- Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1) (PHASE1)
- Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy (PHASE2)
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) (PHASE3)
- Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP) (PHASE3)
- Panhematin for Prevention of Acute Attacks of Porphyria (PHASE2)
- A Study of the Safety, Tolerability and Preliminary Efficacy of B2065 in Patients With Acute Ischemic Stroke. (PHASE1, PHASE2)
- Allogeneic Human Mesenchymal Stem Cell Infusion vs Placebo in Alcohol Use Disorder and Major Depression. (PHASE1, PHASE2)
- Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (human albumin 1%) CI brief — competitive landscape report
- Placebo (human albumin 1%) updates RSS · CI watch RSS
- Biotest portfolio CI
Frequently asked questions about Placebo (human albumin 1%)
What is Placebo (human albumin 1%)?
How does Placebo (human albumin 1%) work?
What is Placebo (human albumin 1%) used for?
Who makes Placebo (human albumin 1%)?
What drug class is Placebo (human albumin 1%) in?
What development phase is Placebo (human albumin 1%) in?
What are the side effects of Placebo (human albumin 1%)?
Related
- Drug class: All Plasma volume expander / Colloid drugs
- Manufacturer: Biotest — full pipeline
- Therapeutic area: All drugs in Critical Care / Hematology
- Indication: Drugs for Placebo control in Phase 3 clinical trial (specific indication unknown)
- Compare: Placebo (human albumin 1%) vs similar drugs
- Pricing: Placebo (human albumin 1%) cost, discount & access